Rating Rationale
August 27, 2021 | Mumbai
IPCA Laboratories Limited
Rating reaffirmed at 'CRISIL A1+'
 
Rating Action
Rs.50 Crore Commercial PaperCRISIL A1+ (Reaffirmed)
1 crore = 10 million
Refer to Annexure for Details of Instruments & Bank Facilities

Detailed Rationale

CRISIL Ratings has reaffirmed its ‘CRISIL A1+’ rating on the commercial paper programme of IPCA Laboratories Ltd (IPCA).

 

IPCA registered healthy revenue growth of 17% year-on-year in fiscal 2021, backed by higher institutional sales and bulk drug sales, including one-off sales of chloroquine (CQ) and hydroxychloroquine (HCQ) in both the domestic and export markets. Revenue growth is expected to remain healthy at 10%-12% over the medium term, supported by growth in the domestic formulations market which contributes ~40% of total revenue. The company continues to maintain leadership position in segments such as rheumatoid arthritis and orthopaedic therapies in the domestic market. Export growth momentum is expected to sustain on the back of healthy growth in bulk drugs segment in the international market and sustenance of sales to institutional customers such as The Global Fund, Geneva.

 

Operating profitability improved sharply to 29.1% in fiscal 2021, against 20.6% in fiscal 2020, supported by healthy revenue growth, lower marketing expenses amidst the Covid-19 pandemic and subsequent lockdown, and high margin on the one-off CQ and HCQ sales. Operating profitability is expected to remain healthy at 23-25% over the medium term. During fiscals 2016 to 2020, IPCA had incurred cost towards remediation of regulatory issues raised by the US Food and Drug Administration (US FDA) at three of its plants, and had invited US FDA for re-inspection. Timely resolution of import alert issued by the US FDA can provide additional uptick to revenue growth and profitability and, hence, will be a key monitorable.

 

Overall, the financial risk profile remains strong. Gearing was comfortable at 0.06 time as on March 31, 2021 (compared to 0.14 time as on March 31, 2020), adjusted interest coverage and net cash accrual to total debt ratios were 144 times and 4.95 times, respectively, in fiscal 2021, against 50 times and 1.44 times, respectively, in fiscal 2020. Absence of any large, debt-funded capital expenditure (capex) and steady accrual is likely to keep the financial risk profile strong over the medium term.

 

The rating continues to reflect IPCA’s established position in the domestic formulations segment, presence in diverse therapeutic segments, integrated operations and strong financial risk profile because of robust capital structure and healthy debt protection metrics. These strengths are partially offset by working capital-intensive operations, exposure to intensifying competition in the pharmaceutical industry, and susceptibility of performance to regulatory changes in the domestic and international markets.

Analytical Approach

For arriving at its rating, CRISIL Ratings has combined the business and financial risk profiles of IPCA and its subsidiaries because of their high operational and financial linkages. For joint ventures (JV) and associates, CRISIL Ratings follows a moderate integration approach. Specifically, CRISIL Ratings factors in any incremental investment required.

 

Please refer Annexure - List of entities consolidated, which captures the list of entities considered and their analytical treatment of consolidation.

Key Rating Drivers & Detailed Description

Strengths:

Established position in domestic formulations, with presence in diverse segments: IPCA is among India’s top 20 pharmaceutical companies. The domestic formulations market contributed 37% of the total revenue in fiscal 2021, against 42% in fiscal 2020. IPCA has established presence in the pain management and cardiovascular segments. Its product portfolio has been expanding in the fast-growing therapeutic segments and the company had a portfolio of 145 brands as on March 31, 2021.

 

Robust financial risk profile: It is backed by substantial networth of Rs 4,555 crore as on March 31, 2021, and healthy capital structure. Debt protection metrics were also comfortable in fiscal 2021. The financial risk profile is expected to sustain, over the medium term, in the absence of any sizeable debt-funded capex.

 

Weaknesses:

Working capital-intensive operations: Gross current assets were 202 days as on March 31, 2021 on account of large inventory and export receivables. The company operates in multiple geographies and has a wide product portfolio. Hence, it is required to maintain substantial inventory to ensure adequate supply. Given its continuously expanding product portfolio, operations are expected to remain working capital intensive over the medium term.

 

Exposure to intense competition and regulatory changes: Around 70% of the revenue is derived from sales of drugs in the pain management, cardiovascular, anti-diabetic and anti-malarial segments, which are intensely competitive. The domestic pharmaceutical sector has recently been subject to increased regulatory scrutiny, adding to the challenges of players. However, this is partially offset by the company’s leadership position in key brands such as Zerodol,

 

Hydroxychloroquine Sulfate, and Solvin. Besides, the company is required to comply with regulations issued by authorities in various countries, given its international presence. The company is exposed to regulatory scrutiny by international authorities, including US FDA and adverse actions could impact the company’s growth prospects, as witnessed in the case of US FDA import alerts on its three plants.

Liquidity: Strong

Liquidity is supported by cash accrual of Rs 1,250 crore in fiscal 2021 and healthy cash and cash equivalent of Rs 758 crore as on March 31, 2021. Cash accrual is expected to be Rs 1,000-1,200 crore over the medium term, which is more than adequate to meet the modest debt obligation of less than Rs 100 crore annually, capex and working capital requirement. Financial flexibility is enhanced by low bank limit utilisation of 41% on average over the 12 months through June 2021, and comfortable gearing of 0.06 time as on March 31, 2021. Liquidity will remain strong over the medium term.

Rating Sensitivity factors

Downward factors

  • Sluggish revenue growth and decline in operating profitability below 15% due to adverse product mix, intense competitive pressures or regulatory issues
  • Large, debt-funded capex or acquisition or stretch in the working capital cycle adversely affecting capital structure and other debt protection metrics
  • Steep decline in liquid surpluses

About the Company

Set up in 1949, IPCA manufactures formulations, active pharmaceutical ingredients (APIs), and drug intermediates. The company’s product range includes pain management, cardiovascular, anti-malarial, anti-emetic, antibiotic, analgesic and anti-diabetic medicines; and formulations for cough and cold therapy, skin problems and problems with the central nervous system. The company is also a leading supplier of APIs such as atenolol (anti-hypertensive), chloroquine and artemisinin derivatives (anti-malarial), furosemide (diuretic) and pyrantel salts (anthelmintic).

 

As on June 30, 2021, the promoters held 46.29% stake in IPCA, foreign portfolio investors held 17.81%, and the balance was held by the public and others.

 

For the first quarter of fiscal 2021, operating income and profit after tax (PAT) were Rs 1,566 crore and Rs 307 crore, respectively, against Rs 1,534 crore and Rs 446 crore, respectively, for the corresponding quarter in the previous fiscal.

Key Financial Indicators

Particulars

Unit

2021

2020

Operating income

Rs crore

5,433

4.656

Adjusted profit after tax (PAT)

Rs crore

1,141

604

Adjusted PAT margin

%

21.0

13.0

Adjusted debt/adjusted networth

Times

0.06

0.13

Adjusted interest coverage

Times

144.00

50.51

 

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL Ratings' complexity levels are assigned to various types of financial instruments. The CRISIL Ratings' complexity levels are available on www.crisil.com/complexity-levels. Users are advised to refer to the CRISIL Ratings' complexity levels for instruments that they consider for investment. Users may also call the Customer Service Helpdesk with queries on specific instruments.

Annexure - Details of Instrument(s)

ISIN

Name of instrument

Date of allotment

Coupon rate (%)

Maturity date

Issue size

(Rs crore)

Complexity Level

Rating assigned

with outlook

NA

Commercial paper

NA

NA

7 to 365 Days

50.00

Simple

CRISIL A1+

 

Annexure – List of entities consolidated

Entity consolidated

Extent of consolidation

Rationale for consolidation

Subsidiaries / Step-down subsidiaries

 

 

IPCA Pharma Nigeria Ltd

Full

Subsidiary (100% holding)

IPCA Pharmaceuticals Ltd, SA. de CV

Full

Subsidiary (100% holding)

IPCA Laboratories (U.K.) Ltd,

Full

Subsidiary (100% holding)

IPCA Pharmaceuticals Inc. USA

Full

Subsidiary (100% holding)

IPCA Pharma (Australia) Pty Ltd

Full

Subsidiary (100% holding)

Tonira Exports Ltd

Full

Subsidiary (100% holding)

Ramdev Chemicals Pvt Ltd

Full

Subsidiary (100% holding)

Trophic Wellness Pvt Ltd

Full

Subsidiary (52.35% holding)

Onyx Scientific Ltd

Full

Step-down subsidiary (100% holding)

IPCA Pharma (NZ) Pty Ltd

Full

Step-down subsidiary (100% holding)

Pisgah Labs Inc

Full

Step-down subsidiary (100% holding)

Bayshore Pharmaceuticals LLC

Full

Step-down subsidiary (80% holding)

Joint venture

 

Avik Pharmaceuticals Ltd

Moderately consolidated

48.99% holding

Associates

 

 

CCPL Software Pvt Ltd

Moderately consolidated

44.67% holding

Krebs Biochemicals & Industries Ltd

Moderately consolidated

28.95% holding

 

Annexure - Rating History for last 3 Years
  Current 2021 (History) 2020  2019  2018  Start of 2018
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund Based Facilities LT   --   --   --   --   -- Withdrawn
Commercial Paper ST 50.0 CRISIL A1+   -- 27-08-20 CRISIL A1+ 29-08-19 CRISIL A1+ 03-08-18 CRISIL A1+ CRISIL A1+
Non Convertible Debentures LT   --   --   --   -- 03-08-18 Withdrawn CRISIL AA-/Stable
Short Term Debt ST   --   --   --   --   -- CRISIL A1+
All amounts are in Rs.Cr.
 
 
    
Criteria Details
Links to related criteria
CRISILs Approach to Financial Ratios
Rating criteria for manufaturing and service sector companies
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating Criteria for the Pharmaceutical Industry
CRISILs Criteria for rating short term debt
CRISILs Criteria for Consolidation

Media Relations
Analytical Contacts
Customer Service Helpdesk
Saman Khan
Media Relations
CRISIL Limited
D: +91 22 3342 3895
B: +91 22 3342 3000
saman.khan@crisil.com

Naireen Ahmed
Media Relations
CRISIL Limited
D: +91 22 3342 1818
B: +91 22 3342 3000
 naireen.ahmed@crisil.com

Anuj Sethi
Senior Director
CRISIL Ratings Limited
B:+91 44 6656 3100
anuj.sethi@crisil.com


Tanvi Kumar Shah
Associate Director
CRISIL Ratings Limited
D:+91 22 4097 8331
tanvi.shah@crisil.com


Parth Shah
Manager
CRISIL Ratings Limited
D:+91 22 3342 4048
Parth.Shah@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL Ratings. However, CRISIL Ratings alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites, portals etc.


About CRISIL Ratings Limited (A subsidiary of CRISIL Limited)

CRISIL Ratings pioneered the concept of credit rating in India in 1987. With a tradition of independence, analytical rigour and innovation, we set the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 33,000 large and mid-scale corporates and financial institutions. We have also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and infrastructure investment trusts (InvITs).
 
CRISIL Ratings Limited ("CRISIL Ratings") is a wholly-owned subsidiary of CRISIL Limited ("CRISIL"). CRISIL Ratings Limited is registered in India as a credit rating agency with the Securities and Exchange Board of India ("SEBI").
 
For more information, visit www.crisilratings.com 




About CRISIL Limited

CRISIL is a global analytical company providing ratings, research, and risk and policy advisory services. We are India's leading ratings agency. We are also the foremost provider of high-end research to the world's largest banks and leading corporations.

CRISIL is majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide


For more information, visit www.crisil.com

Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK


CRISIL PRIVACY NOTICE
 
CRISIL respects your privacy. We may use your contact information, such as your name, address, and email id to fulfil your request and service your account and to provide you with additional information from CRISIL.For further information on CRISIL’s privacy policy please visit www.crisil.com.


DISCLAIMER

This disclaimer forms part of and applies to each credit rating report and/or credit rating rationale (each a "Report") that is provided by CRISIL Ratings Limited  (hereinafter referred to as "CRISIL Ratings") . For the avoidance of doubt, the term "Report" includes the information, ratings and other content forming part of the Report. The Report is intended for the jurisdiction of India only. This Report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL Ratings providing or intending to provide any services in jurisdictions where CRISIL Ratings does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this Report does not create a client relationship between CRISIL Ratings and the user.

We are not aware that any user intends to rely on the Report or of the manner in which a user intends to use the Report. In preparing our Report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the Report is not intended to and does not constitute an investment advice. The Report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind or otherwise enter into any deal or transaction with the entity to which the Report pertains. The Report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Ratings are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities / instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL Ratings assumes no obligation to update its opinions following publication in any form or format although CRISIL Ratings may disseminate its opinions and analysis. Rating by CRISIL Ratings contained in the Report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the Report should rely on their own judgment and take their own professional advice before acting on the Report in any way. CRISIL Ratings or its associates may have other commercial transactions with the company/entity.

Neither CRISIL Ratings nor its affiliates, third party providers, as well as their directors, officers, shareholders, employees or agents (collectively, "CRISIL Ratings Parties") guarantee the accuracy, completeness or adequacy of the Report, and no CRISIL Ratings Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Report. EACH CRISIL RATINGS' PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Ratings Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. CRISIL Rating's public ratings and analysis as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any) are made available on its web sites, www.crisil.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee - more details about ratings by CRISIL Ratings are available here: www.crisilratings.com.

CRISIL Ratings and its affiliates do not act as a fiduciary. While CRISIL Ratings has obtained information from sources it believes to be reliable, CRISIL Ratings does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and / or relies in its Reports. CRISIL Ratings has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL Ratings has in place a ratings code of conduct and policies for analytical firewalls and for managing conflict of interest. For details please refer to: http://www.crisil.com/ratings/highlightedpolicy.html

Rating criteria by CRISIL Ratings are generally available without charge to the public on the CRISIL Ratings public web site, www.crisil.com. For latest rating information on any instrument of any company rated by CRISIL Ratings you may contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (0091) 1800 267 1301.

This Report should not be reproduced or redistributed to any other person or in any form without a prior written consent of CRISIL Ratings.

All rights reserved @ CRISIL Ratings Limited. CRISIL Ratings Limited is a wholly owned subsidiary of CRISIL Limited.

CRISIL Ratings uses the prefix ‘PP-MLD’ for the ratings of principal-protected market-linked debentures (PPMLD) with effect from November 1, 2011 to comply with the SEBI circular, "Guidelines for Issue and Listing of Structured Products/Market Linked Debentures". The revision in rating symbols for PPMLDs should not be construed as a change in the rating of the subject instrument. For details on CRISIL Ratiings' use of 'PP-MLD' please refer to the notes to Rating scale for Debt Instruments and Structured Finance Instruments at the following link: www.crisil.com/ratings/credit-rating-scale.html